[go: up one dir, main page]

RU99104300A - CRYSTALLINE MODIFICATION OF PHARMACEUTICAL AGENT - Google Patents

CRYSTALLINE MODIFICATION OF PHARMACEUTICAL AGENT

Info

Publication number
RU99104300A
RU99104300A RU99104300/04A RU99104300A RU99104300A RU 99104300 A RU99104300 A RU 99104300A RU 99104300/04 A RU99104300/04 A RU 99104300/04A RU 99104300 A RU99104300 A RU 99104300A RU 99104300 A RU99104300 A RU 99104300A
Authority
RU
Russia
Prior art keywords
modification
difluorobenzyl
triazole
carboxamide
paragraphs
Prior art date
Application number
RU99104300/04A
Other languages
Russian (ru)
Other versions
RU2198167C2 (en
Inventor
Портманн Роберт
Кристоф Хофмайер Урс
Буркхард Андреас
Шеррер Вальтер
Шелагевич Мартин
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU99104300A publication Critical patent/RU99104300A/en
Application granted granted Critical
Publication of RU2198167C2 publication Critical patent/RU2198167C2/en

Links

Claims (1)

1. Модификация А соединения 1-(2,6-дифторбензил)-1Н-1,2,3-триазол-4-карбоксамида формулы
Figure 00000001

отличающаяся характеристическими линиями, соответствующими межплоскостным расстояниям (величины d)
Figure 00000002
по данным порошкового ренгеноструктурного анализа.1. Modification A of the compound 1- (2,6-difluorobenzyl) -1H-1,2,3-triazole-4-carboxamide of the formula
Figure 00000001

characterized by characteristic lines corresponding to interplanar distances (d values)
Figure 00000002
according to powder x-ray diffraction analysis. 2. Модификация по п. 1, отличающаяся тем, что ее порошковая ренгенограмма имеет следующие характеристические линии, соответствующие межплоскостным расстояниям (величины d)
Figure 00000003

3. Модификация по п. 1 или 2, отличающаяся наличием следующих поглощений в инфракрасном спектре с преобразованием Фурье (ИК-ПФ-спектре) (метод трансмиссии на таблетках KBr): при 3092 см-1 и 3412 см-1.2. The modification according to claim 1, characterized in that its powder X-ray diffraction pattern has the following characteristic lines corresponding to interplanar distances (d values)
Figure 00000003

3. The modification according to claim 1 or 2, characterized by the presence of the following absorption in the infrared spectrum with the Fourier transform (IR-PF spectrum) (transmission method on KBr tablets): at 3092 cm -1 and 3412 cm -1 . 4. Модификация по п. 3, отличающаяся наличием следующих поглощений в ИК-ПФ-спектре (метод трансмиссии на таблетках KBr): при 3412, 3189, 3092 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 и 640 см-1.4. The modification according to claim 3, characterized by the presence of the following absorption in the IR-PF spectrum (transmission method on KBr tablets): at 3412, 3189, 3092 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 cm -1 . 5. Модификация по любому из пп. 1 - 4, отличающаяся наличием следующих поглощений в спектре комбинационного рассеяния с преобразованием Фурье (КР-ПФ-спектре) (метод отражения на 180° на порошке) при: 3093, 2972, 1628, 1614. 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 и 368 см-1.5. Modification according to any one of paragraphs. 1 - 4, characterized by the presence of the following absorption in the Raman spectrum with the Fourier transform (Raman spectrum) (reflection method at 180 ° on the powder) at: 3093, 2972, 1628, 1614. 1558, 1465, 1446, 1393, 1279 , 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 cm -1 . 6. Модификация А по любому из пп. 1 - 5, отличающаяся наличием эндотермического пика в диапазоне от 230 до 260°С, причем температура пика равна 239-245°С, а эндотермический сигнал составляет 209±10 Дж/г. 6. Modification A according to any one of paragraphs. 1 to 5, characterized by the presence of an endothermic peak in the range from 230 to 260 ° C, and the peak temperature is 239-245 ° C, and the endothermic signal is 209 ± 10 J / g 7. Модификация А' соединения 1-(2,6-дифторбензил)-1Н-1,2,3-триазол-4-карбоксамида, отличающаяся тем, что она идентична модификации А по любому из пп. 1 - 6, но имеет дефекты в кристаллической решетке. 7. Modification A 'of compound 1- (2,6-difluorobenzyl) -1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to modification A according to any one of paragraphs. 1 - 6, but has defects in the crystal lattice. 8. Модификация А' по п. 7, отличающаяся тем, что по сравнению с модификацией А имеет меньшие расстояния между парами линий со следующими межплоскостными расстояниями:
Figure 00000004

9. Модификация А или А' по любому из пп. 1 - 8 в практически чистой форме.8. Modification A 'according to claim 7, characterized in that, compared with modification A, it has smaller distances between pairs of lines with the following interplanar distances:
Figure 00000004

9. Modification A or A 'according to any one of paragraphs. 1 - 8 in almost pure form. 10. Фармацевтические композиции, содержащие модификацию А или А' соединения 1-(2,6-дифторбензил)-1Н-1,2,3-триазол-4-карбоксамида по любому из пп. 1 - 9 и фармацевтически пригодные эксципиенты и добавки. 10. Pharmaceutical compositions containing modification A or A ′ of the compound 1- (2,6-difluorobenzyl) -1H-1,2,3-triazole-4-carboxamide according to any one of claims. 1 to 9 and pharmaceutically acceptable excipients and additives. 11. Применение модификации А или А' 1-(2,6-дифторбензил)-1Н-1,2,3-триазол-4-карбоксамида по любому из пп. 1 - 9 в качестве фармацевтической композиции. 11. The use of modification A or A '1- (2,6-difluorobenzyl) -1H-1,2,3-triazole-4-carboxamide according to any one of paragraphs. 1 to 9 as a pharmaceutical composition. 12. Применение модификации А или А' 1-(2,6-дифторбензил)-1Н-1,2,3-триазол-4-карбоксамида по любому из пп. 1 - 9 при изготовлении фармацевтических композиций, предназначенных для лечения эпилепсии или ее подсимптомов. 12. The use of modification A or A '1- (2,6-difluorobenzyl) -1H-1,2,3-triazole-4-carboxamide according to any one of paragraphs. 1 to 9 in the manufacture of pharmaceutical compositions intended for the treatment of epilepsy or its sub-symptoms. 13. Модификация соединения 1-(2,6-дифторбензил)-1Н-1,2,3-триазол-4-карбоксамида, отличающаяся наличием полос в ИК-ПФ-спектре при 3412 см-1 и 3092 см-1.13. Modification of the compound 1- (2,6-difluorobenzyl) -1H-1,2,3-triazole-4-carboxamide, characterized by the presence of bands in the IR-PF spectrum at 3412 cm -1 and 3092 cm -1 . 14. Модификация соединения 1-(2,6-дифторбензил)-1Н-1,2,3-триазол-4-карбоксамида, отличающаяся наличием полосы в КР-ПФ-спектре при 1080 см-1.14. Modification of the compound 1- (2,6-difluorobenzyl) -1H-1,2,3-triazole-4-carboxamide, characterized by the presence of a band in the Raman-PF spectrum at 1080 cm -1 . 15. Фармацевтическая композиция, содержащая модификацию по п. 13 или 14 и фармацевтически приемлемые эксципиенты и добавки. 15. A pharmaceutical composition comprising the modification of Claim 13 or 14 and pharmaceutically acceptable excipients and additives.
RU99104300/04A 1997-06-10 1998-06-08 Crystalline modifications of 1-(2,6-difluorobenzyl)-1h-1,2,3-trazol-4-carboxamide and pharmaceutical composition RU2198167C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10
CH1404/97 1997-06-10

Publications (2)

Publication Number Publication Date
RU99104300A true RU99104300A (en) 2000-12-27
RU2198167C2 RU2198167C2 (en) 2003-02-10

Family

ID=4209650

Family Applications (2)

Application Number Title Priority Date Filing Date
RU99104300/04A RU2198167C2 (en) 1997-06-10 1998-06-08 Crystalline modifications of 1-(2,6-difluorobenzyl)-1h-1,2,3-trazol-4-carboxamide and pharmaceutical composition
RU99104299/04A RU2194041C2 (en) 1997-06-10 1998-06-08 Crystalline modifications b and c of 1-(2,6-difluoro-benzyl)-1h-1,2,3-triazole-4-carboxamide and pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU99104299/04A RU2194041C2 (en) 1997-06-10 1998-06-08 Crystalline modifications b and c of 1-(2,6-difluoro-benzyl)-1h-1,2,3-triazole-4-carboxamide and pharmaceutical composition

Country Status (36)

Country Link
US (6) US6740669B1 (en)
EP (2) EP0994863B1 (en)
JP (2) JP3672574B2 (en)
KR (2) KR100425656B1 (en)
CN (3) CN1132820C (en)
AR (4) AR012946A1 (en)
AT (2) ATE237599T1 (en)
AU (2) AU725528B2 (en)
BR (2) BR9804946A (en)
CA (3) CA2256013C (en)
CO (2) CO4940452A1 (en)
CY (1) CY2007014I2 (en)
CZ (2) CZ292481B6 (en)
DE (3) DE122007000051I2 (en)
DK (2) DK0994863T3 (en)
ES (2) ES2197485T3 (en)
FR (1) FR07C0037I2 (en)
HU (2) HU226107B1 (en)
ID (2) ID21014A (en)
IL (2) IL125732A (en)
LU (1) LU91345I2 (en)
MY (2) MY125854A (en)
NL (1) NL300284I2 (en)
NO (2) NO329315B1 (en)
NZ (2) NZ331371A (en)
PE (2) PE80999A1 (en)
PL (2) PL191943B1 (en)
PT (1) PT994864E (en)
RU (2) RU2198167C2 (en)
SI (2) SI0994863T1 (en)
SK (2) SK283685B6 (en)
TR (2) TR199801631T1 (en)
TW (2) TW526195B (en)
UY (1) UY25844A1 (en)
WO (2) WO1998056773A1 (en)
ZA (2) ZA984966B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW526195B (en) 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
MXPA04011865A (en) * 2002-05-31 2005-03-31 Schering Corp Xanthine phosphodiesterase v inhibitor polymorphs.
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
JP2012505191A (en) * 2008-10-13 2012-03-01 シプラ・リミテッド Method for producing rufinamide
CN101768124B (en) * 2008-12-30 2012-01-04 北京本草天源药物研究院 Medicine crystal, preparation method and purpose thereof
IT1395736B1 (en) * 2009-08-04 2012-10-19 Dipharma Francis Srl CRYSTALLINE FORMS OF RUFINAMIDE
CA2772075C (en) * 2009-09-04 2017-02-28 Rashida A. Karmali Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
EP2465853A1 (en) 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
US8884026B2 (en) 2010-04-30 2014-11-11 Laboratorios Lesvi, S.L. Process for preparing rufinamide intermediate
ITMI20110718A1 (en) 2011-04-29 2012-10-30 Dipharma Francis Srl PROCEDURE FOR PURIFICATION OF RUFINAMIDE
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
FI834666A7 (en) 1982-12-23 1984-06-24 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA ARALKYLTRIAZOLFOERENINGAR.
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
FI93544C (en) * 1985-04-18 1995-04-25 Ciba Geigy Ag Process for the preparation of fluorinated 1-benzyl-1H-1,2,3-triazole compounds with anticonvulsant action
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (en) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd Method for depositing crystal of compound having plural crystal forms
EP0484437A4 (en) 1989-07-27 1994-06-01 Searle & Co Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP2550456B2 (en) 1990-11-06 1996-11-06 山之内製薬株式会社 Fused pyrazine derivative
JP2753911B2 (en) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Crystal polymorph of N-tert-butyl-1-methyl-3,3-diphenylpropylamine hydrochloride and method for producing the same
DE4217952A1 (en) 1992-05-30 1993-12-02 Basf Ag Quinoxaline-2,3 (1H, 4H) diones
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
PT812320E (en) 1995-02-22 2000-12-29 Aventis Pharma Ltd AMORFO PYRETANID POLYMORPHINE FIRETHANE PROCESS FOR THEIR PREPARATION AND ITS UTILIZATION
CZ294775B6 (en) * 1996-07-11 2005-03-16 Novartis Ag Process for preparing 1-substituted 4-cyano-1,2,3-triazoles
TW526195B (en) 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use

Similar Documents

Publication Publication Date Title
RU99104300A (en) CRYSTALLINE MODIFICATION OF PHARMACEUTICAL AGENT
CA2192418C (en) New crystal modification of cdch, a process for its preparation and pharmaceutical formulations comprising this modification
KR100431038B1 (en) Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Atorvastatin)
RU99104299A (en) CRYSTAL MODIFICATION OF PHARMACEUTICAL AGENT
US6121461A (en) Form III crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
RU2328489C3 (en) CRYSTALLINE FORM OF SALT 4- (3-CHLORO-4- (CYCLOPROPYLAMINOCARBONIL) AMINOPHENOXY) -7-METOXY-6-QUINOLINCARBOXAMIDE OR SOLVATE OF THIS SALT AND METHODS FOR PRODUCING IT
ES8200665A1 (en) Sulfonyl ureas, processes for their preparation and pharmaceutical compositions containing these compounds.
CY2121B1 (en) Derivatives of amidinophenylalanine procedure for their preparation their utilisation and compositions comprising them
RU93054537A (en) DERIVATIVES OF GUANIDINALKYL-1,1-BISPHOSPHONIC ACID, METHOD FOR PRODUCING AND USING THEM
ES499485A0 (en) PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF CEPHALOSPO-RINA
AR015418A1 (en) PROCEDURE FOR THE PREPARATION OF THE CRYSTAL FORM (MODIFICATION 1) OF THE N- (TRIFLUORMETHYL-PHENYL) -5-METHYL-ISOXAZOL-4-CARBOXAMIDE.
EA008441B1 (en) CRYSTALLINE [R-(R,R)]-2(4-FLUOROPHENYL)- β δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL -4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1)
CA2614926A1 (en) Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
JP2002308895A5 (en)
NO177961C (en) Analogous process for the preparation of tetrazole-substituted benzonitriles
RU98103388A (en) (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION
ES466851A1 (en) PROCEDURE FOR THE PREPARATION OF 2-BROMO-6-FLUOR-N-2- IMIDAZOLIDINILIDENBENZAMINA.
PL283722A1 (en) Method for manufacturing phenylhydrazones
GB2014990A (en) Process for preparing an optically active benzamide, the optically active benzamide so obtained and pharmaceutical compositions containing it
CA2225022A1 (en) New polymorphous form of doxazosine mesylate (form iii)
ES2150105T3 (en) PIRETANIDA AMORFA, POLYMORPHOS OF PIRETANIDA, PROCESS FOR ITS PREPARATION AND USE.
RU98102187A (en) APPLICATION OF ALLYLAMINE DERIVATIVES, SUCH AS TERBINAFIN, IN THE MANUFACTURE OF A MEDICINE FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION OR ASSOCIATED DISEASES
SU523085A1 (en) M-, p-iodophenylhydrazides dimethyl or diethylglycolic acids exhibiting anticonvulsant activity
RU94019424A (en) Method of preparing crystalline loracarbef monohydrate from crystalline loracarbef dihydrate
AU1264188A (en) 1-(1-aryl-2-hydroxyethyl)-imidazoles and salts thereof, processes for the preparation thereof, medicaments containing these compounds, and the use thereof